Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.


Precision of Liquid Biopsy and Osimertinib Resistance

From Globe Newswire Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy in comparison to tissue biopsy. Two…


Current Open Clinical Trials

From UCLA Thoracic Oncology Translational Research Current and open clinical trials have been announced at UCLA Main Campus and various satellite centers. The trials include:  Clinical Trial: Relapsed or Refractory Small Cell Lung Cancer …


FDA approves new treatment for extensive-stage small cell lung cancer

From Combination Therapy for SCLC On March 18, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with carboplatin and etoposide, for the first-line treatment of adult patients …


El Paso County Public Health advises people to test homes for radon

From COLORADO SPRINGS, Colo. (KKTV) January was National Radon Action Month Radon and Lung cancer: “Radon is a clear, odorless, colorless radioactive gas that seeps through the soil from the breakdown of uranium,” said Marla Luckey,…


Antibiotics or anti-inflammatory drugs may help combat lung cancer

from MIT News Bacteria promote lung tumor development, study suggests MIT cancer biologists have discovered a new mechanism that lung tumors exploit to promote their own survival: These tumors alter bacterial populations within the lung, pr…


New Treatment Options for ROS1, BRAF, and NTRK Alterations in NSCLC

from OncLive The scope of targeted therapies has extended more in non–small cell lung cancer (NSCLC), especially with the recent FDA approval of larotrectinib (Vitrakvi) for patients with NTRK gene fusions irrespective of the primary tumor…


Molecular profiling could catch lung cancer early and lead to new treatments

From Medical Express Molecular profiling to catch lung cancer early The world's first genetic sequencing of precancerous lung lesions could pave the way for very early detection and new treatments, reports a new study led by University Coll…


New Protein Found Linked to Lung Cancer Treatment Resistance

From MedExpress Lung cancer remains a major cause of mortality across the globe, although we are gaining a deeper understanding of the genetic background behind this disease, including the mutations that promote it. Mutation in the gene EGFR…


What happens when the doctor blames you for your own cancer?

How bias in the medical community hurts lung cancer patients. from The Washington Post Not long ago, I was working in a busy teaching hospital’s intensive-care unit, poring over EKGs, examining X-rays and reviewing medication orders. I re…


Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis

from EurekAlert University of Colorado Study Patients now living a median 6.8 years: According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chan…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson